SEARCH

SEARCH BY CITATION

References

  • 1
    Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:15721573.
  • 2
    Freeman J, Noon L. Further observation on the treatment of hay-fever by hypodermic inoculation of pollen vaccine. Lancet 1911; 2:814817.
  • 3
    Kroon AM. The EAMG position on the regulation of existing products for treatment with special reference to named patient products (NPPs). Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf AM 2003; 94:714.
  • 4
    The European Parliament and Council. Directive 2001/83/EC. The community code relating to medicinal products for human use. OJ 2004;L311:67122.
  • 5
    The European Parliament and Council. Directive 2001/20/EC on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. OJ 2001;L121:2444.
  • 6
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. 2008, CHMP/EWP/18504/2006.
  • 7
    Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317324.
  • 8
    Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R et al. Sub-Lingual Immunotherapy. World Allergy Organization Position Paper 2009. Chapter 11: Methodology of Clinical Trials in Sublingual Immunotherapy. Allergy 2009;64(Suppl. 91):5159.
  • 9
    Casale TB, Canonica GW, Bousquet J, Cox L, Lockey R, Nelson HS et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009;124:665670.
  • 10
    Himly M, Nony E, Chabre H, Van Overtvelt L, Neubauer A, van Ree R et al. Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation. Allergy 2009;64:10381045.
  • 11
    Reuter A, Lüttkopf D, Vieths S. New frontiers in allergen standardization. Clin Exp Allergy 2009;39:307309.
  • 12
    Chapman MD, Ferreira F, Villalba M, Cromwell O, Bryan D, Becker WM et al, CREATE consortium. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J Allergy Clin Immunol 2008;122: 882889.
  • 13
    Pauli G. Clinical trials with recombinant allergens. Research studies?. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2009;96:257264.
  • 14
    Monograph on Allergen Products, European Pharmacopoeia 01/2010:1063.
  • 15
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) and Biologics Working Party (BWP): Guideline on Allergen Products: Production and Quality Issues. 2008. EMEA/CHMP/BWP/304831/2007.
  • 16
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic Q 5 B/Note for Guidance on quality of biotechnological products: Analysis of the expression construct in cell lines used for production of r-DNA derived protein products. 2005; CPMP/ICH/139/95.
  • 17
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic Q 5 C/Note for Guidance on Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. 1996; CPMP/ICH/138/95.
  • 18
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic Q 5 D/Note for Guidance on quality of biotechnological products: derivation and characterisation of cell substrates used for production of biotechnological/biological products. 1997; CPMP/ICH/294/95.
  • 19
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic Q 5 E/Note for Guidance on Quality of Biotechnological/Biological Products subject to Changes in Their Manufacturing Process. 2005; CPMP/ICH/5721/03.
  • 20
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic Q 6 B/Note for Guidance on specifications: test procedures and acceptance criteria for biotechnological/ biological products. 1999; CPMP/ ICH/365/96.
  • 21
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic S 6 C/Note for Guidance on quality of biotechnological products: stability testing of biotechnological/ biological products. 1995; CPMP/ICH/ 138/95.
  • 22
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and Biotechnology Working Party (BWP): Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: quality issues. 2003; EMEA/CPMP/BWP/ 3207/00/Rev1.
  • 23
    The Commission of the European Communities. Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. OJ 2003;L159:4694.
  • 24
    The Commission of the European Communities. Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use. OJ 2003;262:2226.
  • 25
    The European Parliament Council. Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. OJ 2004;136:133.
  • 26
    The European Parliament Council. Regulation (EC) No 1901/2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. OJ 2006; 378:119.
  • 27
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic Q 7/Note for Guidance on Good Manufacturing Practice for active pharmaceutical Ingredients. 2000; CPMP/ICH/4106/00.
  • 28
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic M 3 (R2)/Note for Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. 2009; CPMP/ICH/286/95.
  • 29
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic S2 (R1)/Note for Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. Draft. 2008; EMEA/CHMP/ICH/126642/2008.
  • 30
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic S2A/Note for Guidance on Genotoxicity: Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals. 1996; CPMP/ICH/141/95.
  • 31
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic 2B/Note for Guidance on Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals. 1998; CPMP/ICH/174/95.
  • 32
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic S4/Note for Guidance on Duration of Chronic Toxicity Testing in Animals (Rodent and Non-Rodent Toxicity Testing). 1999; CPMP/ICH/300/95.
  • 33
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic S5 (R2)/Note for Guidance on the Detection of Toxicity to Reprodution for Medicinal Products & Toxicity to Male Fertility. 1994; CPMP/ICH/386/95.
  • 34
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic S6/Note for Guidance on preclinical safety evaluation of biotechnology-derived pharmaceuticals. 1998; CPMP/ICH/302/95.
  • 35
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Preclincal Pharmacological and Toxicological Testing of Vaccines. 1998; CPMP/SWP/465/95.
  • 36
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Questions and answers on the withdrawal of the ‘Note for guidance on single dose toxicity’. 2010; EMA/CHMP/SWP/81714/2010.
  • 37
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on repeated dose toxicity. 2010; CPMP/SWP/1042/99 Rev 1 Corr.
  • 38
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). EMA Guideline on the Need for Non-Clinical Testing in Juvenile Animals of Pharmaceuticals for Paediatric Indications. 2008; EMEA/CHMP/SWP/169215/2005.
  • 39
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Non-Clinical Local Tolerance Testing of Medicinal Products. 2001; CPMP/SWP/2145/00.
  • 40
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic E 1/Note for Guidance on Population Exposure: The Extent of Population Exposure to Assess Clinical Safety. 1995; CPMP/ICH/375/95.
  • 41
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic E 6 (R1)/Note for Guidance on Good Clinical Practice. 2002; CPMP/ICH/135/95.
  • 42
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic E 9/Note for Guidance on Statistical Principles for Clinical Trials. 1998; CPMP/ICH/363/96.
  • 43
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Topic E 11/Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population. 2001; CPMP/ICH/2711/99.
  • 44
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP). Points to Consider on Application with 1. Meta-Analysis; 2. One Pivotal Study. 2001; CPMP/EWP/2330/99.
  • 45
    European Medicines Agency (EMA). Standard Paediatric Investigation Plan (EMA/PDCO/737605/2009) (Revision 2), 3 March 2010.
  • 46
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on Risk Assessment of Medicinal Products on Human Reproduction and Lactation: From Data to Labelling. 2009; EMEA/CHMP/203927/2005.
  • 47
    Bousquet J, Lockey RF, Malling HJ. WHO Position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(Suppl. 44):142.
  • 48
    Malling HJ, Weeke B. EAACI Immunotherapy position paper. Allergy 1993;48(Suppl. 14):945.
  • 49
    European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Draft Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials. 2008; EMEA/CHMP/BWP/534898/2008.
  • 50
    Verordnung über die Ausdehnung der Vorschriften über die Zulassung der Arzneimittel auf Therapieallergene, die für einzelne Personen auf Grund einer Rezeptur hergestellt werden, sowie über Verfahrensregelungen der staatlichen Chargenprüfung (Therapieallergene-Verordnung). Bundesgesetzblatt I 2008;51:2177–2178.
  • 51
    Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz). Bundesgesetzblatt I 2005; S 3394 amended by 15. AMG Novelle. Bundesgesetzblatt I 2009;43:19902020 and 69:3578.
  • 52
    Guideline on the definition of a potential serious risk to public health in the context of Article 29(1) and (2) of Directive 2001/83/EC – March 2006 (2006/C 133/05). OJ 2006;C133:57.
  • 53
    The Council of the European Communities. Directive 89/342/EEC extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for immunological medicinal products consisting of vaccines, toxins or serums and allergens. OJ 1989;L142:1415.
  • 54
    The European Parliament and Council. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. OJ 2004;L136: 3457.
  • 55
    May S, Kaul S, Lüttkopf D, Vieths S. Regulation, role and future of named patient products in Germany. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf AM 2009;96:193197.
  • 56
    Ministère de la santé et des solidarités. Décret n8 2004-188 du 23 février 2004 relatif aux allergènes préparés spécialement pour un seul individu et modifiant le code de la santé publique. OJ 2004;50:4101 texte n8 30.
  • 57
    European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) and Biotechnology Working Party (BWP). Note for guidance on allergen products. 1996; CPMP/BWP/243/96, replaced by EMEA/CHMP/ BWP/304831/2007.
  • 58
    Elferink AFA. Clinical trials with recombinant allergens – a regulatory perspective. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe biomedizinische Arzneimittel 2009;96:266299.